The Relationship Between Early Motor Repertoire Quality and Later-term Motor Function in Children With CP

March 26, 2026 updated by: osman coban, Uskudar University
Cerebral palsy (CP) is a group of disorders attributed to non-progressive disorders occurring in the developing fetal, infantile brain, affecting posture, movement development, and activity limitations. It occurs in approximately 2 to 2.5 per 1,000 live births. The prognosis for gross motor function among children with CP is extremely variable. This variability poses a significant challenge to scientific definitions of motor function for clinicians who regularly deal with practical issues such as examination, prognosis, intervention planning, and outcome assessment in children with CP. Observing the general quality of movement of preterm or term babies can be used to identify babies at risk of developing neurological disorders and can provide information about possible future motor function.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

They frequently use the 66-item Gross Motor Function Measurement (GMFM-66) to evaluate gross functions and the Gross Motor Function Classification System (GMFCS) to classify gross motor functions. It is important to use the data obtained from these methods to assist in examination, prognosis, intervention planning and outcome evaluation for children with CP. In addition, the Motor Optimality Score (MOS), which is based on observing the quantity and quality of movement patterns, is used. When we look at the literature, there are very few studies comparing the amount and quality of the motor repertoire obtained using the early motor optimality score with the motor functions in the later period. Therefore, in this study, in addition to evaluating general movements in early infancy (3-5 months), it is aimed to predict the motor function in the future by evaluating the quality and amount of motor repertoire (motor optimality score, MOS) (movement and posture of the baby).

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Ataşehir
      • Istanbul, Ataşehir, Turkey (Türkiye), 34750
        • Türkiye Spastik Çocuklar Vakfı

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Children diagnosed with Cerebral Palsy who applied to the Turkish Spastic Children Foundation for evaluation between 2011 and 2023 and whose Prechtl Analysis shots were archived between the 10th and 20th weeks will be included in the study.

Description

Inclusion Criteria:

  • Children with a diagnosis of Cerebral Palsy
  • Children who applied to the Turkish Spastic Children Foundation between 2011-2023
  • Availability of Prechtl General Movements Assessment recordings obtained between 10-20 weeks post-term age
  • Availability of GMFM-66 assessment data

Exclusion Criteria:

  • Lack of parental or legal guardian consent
  • Presence of additional diagnoses affecting motor assessment
  • Cases where GMFM-66 evaluation was not applicable
  • Incomplete clinical records

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
1
Babies aged between 3 months and 5 months (corrected age) who applied to the Turkish Spastic Children Foundation for risky baby evaluation between 2011 and 2023, whose videos were recorded for GM's evaluation, and who were later diagnosed with cerebral palsy will be included in the study. The quality of the early engine repertoire will be evaluated with MOS (Motor Optimality Score) based on GM's video footage. The evaluation will be carried out by a physiotherapist who has received advanced GM's evaluation training.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Motor Optimality Score (MOS)
Time Frame: 3 months
Motor optimality score (MOS) have 5 categories to the score. These are fidgety movements (max 12 points), repertoire of co-existent other movements (max 4 points), quality of other movements (max 4 points), posture (max 4 points) and movement character (max 4 points). The category scores are added to a max of 28 points.
3 months
Gross Motor Function Measurement (GMFM-66)
Time Frame: 3 months
The Gross Motor Function Measure (GMFM) is a tool that has been developed to assess change in gross motor function in children with cerebral palsy aged 5 months to 16 years of age.1 The GMFM measures 'activity' as defined within the Interna- tional Classification of Functioning, Disability and Health.2 To administer the GMFM, a trained therapist observes the child completing a number of gross motor tasks in a standardised environment, and the child's best ability is measured.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Uskudar University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: osman çoban, phd, Uskudar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 30, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 30, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 23, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 23, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 27, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 30, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 26, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Uskudaraysesav

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

After we complete the study, results will be shared

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings